Recent experience with fungaemia: change in species distribution and azole resistance

References

• Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of haematogenous candidiasis caused by different Candida spp. Clin Infect Dis 1997; 24: 1122–8
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133–63
   PubMed Web of Science ®Google Scholar
• Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a 3-y analysis. Clin Infect Dis 1999; 29: 239–44
   PubMed Web of Science ®Google Scholar
• Harvey RL, Myers JP. Nosocomial fungaemia in a large community teaching hospital. Arch Intern Med 1987; 147: 2117–20
   PubMedGoogle Scholar
• Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidaemia in patients without neutropenia. Candidaemia Study Group and the National Institute. N Eng J Med 1994; 331: 1325–30
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. National Nosocomial Infections Surveillance System, Hospitals. Secular trend of hospital acquired candidaemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 2002; 35: 627–30
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Infectious Diseases Society of America. Guidelines for the treatment of candidiasis. Clin Infect Dis 2004; 38: 161–89
   PubMed Web of Science ®Google Scholar
• Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungaemia: experience in a tertiary care centre. Clin Infect Dis 2005; 41: 975–81
   PubMed Web of Science ®Google Scholar
• Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21: 606–25
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Ghosh A, Batra R, Kaushal A, Roy P, Singh H. Antifungal susceptibility pattern of non-albicans Candida species and distribution of species isolated from candidaemia cases over a 5-y period. Indian J Med Res 1996; 104: 171–6
   PubMed Web of Science ®Google Scholar
• Prasad KN, Agarwal J, Dixit AK, Tiwari DP, Dhole TN, Ayyagari A. Role of yeasts as nosocomial pathogen and their susceptibility to fluconazole and amphotericin B. Indian J Med Res 1999; 110: 11–7
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Mohan B, Shrivastava SK, Marak RS, Ghosh A, Ray P. Change in distribution and antifungal susceptibility of Candida species isolated from candidaemia cases in a tertiary care centre during 1996–2000. Indian J Med Res 2002; 116: 5–12
   PubMed Web of Science ®Google Scholar
• Rani R, Mohapatra NP, Mehta G, Randhawa VS. Changing trends of Candida species in neonatal septicaemia in a tertiary care north Indian hospital. Indian J Med Microbiol 2002; 20: 42–4
   PubMedGoogle Scholar
• Verma AK, Prasad KN, Singh M, Dixit AK, Ayyagari A. Candidaemia in patients of a tertiary health care hospital from north India. Indian J Med Res 2003; 117: 122–8
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Singh K, Narang A, Singhi S, Batra R, Rao KL, et al. Outbreak of Pichia anomala infection in the paediatric service of a tertiary care centre in northern India. J Clin Microbiol 2001; 39: 1702–6
   PubMed Web of Science ®Google Scholar
• Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. Manual of Clinical Microbiology8th edn, PR Murray, EJ Baran, JH Jorgensen, MA Pfaller, RH Yolker. ASM Press, Washington DCUSA 2003; 2: 1693–1711
   Google Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd edn Approved Standard M27-A2(NCCLS, Wayne, PA, USA). 2002.
   Google Scholar
• Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–26
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Chander J, Kasturi P, Panigrahi D. Candidaemia: a 10-y study in an Indian teaching hospital. Mycoses 1992; 35: 47–51
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidaemia: epidemiology, therapy, and influences on mortality in hospitalized adult and paediatric patients. Clin Infect Dis 2003; 37: 634–43
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicentre study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177–86
   PubMed Web of Science ®Google Scholar
• Sobel JD, Rex JH. Invasive candidiasis: turning risk into practical prevention policy?. Clin Infect Dis 2001; 33: 187–90
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857–63
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(Suppl 2)S89–94
   PubMed Web of Science ®Google Scholar
• Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in 7 surgical intensive care units and 6 neonatal intensive care units. Clin Infect Dis 1999; 29: 253–8
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Singh K, Das S. Changing face of nosocomial candidaemia. Indian J Med Microbiol 1999; 17: 160–6
   Google Scholar
• Colombo AL, Nucci M, Salomao R, Branchini ML, Richtmann R, Derossi A, Wey SB. High rate of non-albicans candidaemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281–6
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, et al. Candida guillermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS Disk Antifungal Surveillance Programme. J Clin Microbiol 2006; 44: 3551–6
   PubMed Web of Science ®Google Scholar
• Masala L, Luzzati R, Maccacaro L, Antozzi L, Concia E, Fontana R. Nosocomial cluster of Candida guillermondii fungaemia in surgical patients. Eur J Clin Microbiol Infect Dis 2003; 22: 686–8
   PubMed Web of Science ®Google Scholar
• Aragão PA, Oshiro IC, Manrique EI, Gomes CC, Matsuo LL, Leone C, et al. IRIS Study Group. Pichia anomala outbreak in a nursery: exogenous source?. Pediatr Infect Dis J 2001; 20: 843–8
   PubMed Web of Science ®Google Scholar
• Kalenic S, Jandrlic M, Vegar V, Zuech N, Sekulic A, Mlinaric-Missoni E. Hansenula anomala outbreak at a surgical intensive care unit: a search for risk factors. Eur J Epidemiol 2001; 17: 491–6
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Sukiennik TC, Severo LC, de Amorim CS, Colombo AL. An outbreak of Pichia anomala fungaemia in a Brazilian paediatric intensive care unit. Infect Control Hosp Epidemiol 2005; 26: 553–8
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age?. Clin Infect Dis 2002; 35: 982–9
   PubMed Web of Science ®Google Scholar
• Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43: S15–27
   Web of Science ®Google Scholar
• Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JJ, et al. Candidaemia in a tertiary care cancer centre: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 2003; 82: 309–21
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Sheehan DJ. Interpretative breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435–47
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Results from ARTEMIS DISK Global Antifungal surveillance study: a 6.5-y analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standard disk diffusion testing. J Clin Microbiol 2005; 43: 5848–59
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Programme. Diagn Microbiol Infect Dis 2004; 48: 201–5
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanism of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chenotherer 2005; 49: 668–79
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: 4 y of global surveillance. J Clin Microbiol 2006; 44: 760–3
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Vidal L, Goldberg S, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clinic Proc 2008; 83: 1011–21
   PubMed Web of Science ®Google Scholar
• Baddley JW, Patel M, Jones M, Cloud G, Smith AC, Moser SA. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidaemia. Diagn Microbiol Infect Dis 2004;50:119–24.
   PubMed Web of Science ®Google Scholar